Current Report Filing (8-k)

Date : 10/15/2019 @ 9:18PM
Source : Edgar (US Regulatory)
Stock : Interpace Biosciences Inc (IDXG)
Quote : 0.66  -0.0289 (-4.20%) @ 1:00AM

Current Report Filing (8-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 10, 2019

 

INTERPACE DIAGNOSTICS GROUP, INC.

(Exact name of Registrant as specified in its charter)

 

DELAWARE   0-24249   22-2919486

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

Morris Corporate Center 1, Building C

300 Interpace Parkway,

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

 

(855) 776-6419

Registrant’s telephone number, including area code:

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value per share   IDXG   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On October 10, 2019, Interpace Diagnostics Group, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following proposals were voted on and approved by the Company’s stockholders at the Annual Meeting with the stockholders having voted as set forth below:

 

Proposal 1: To elect one Class I member of the Board of Directors of the Company, who will serve for a term of three years and until such director’s successor is elected and qualified.

 

    For   Withhold   Broker Non-Vote
Stephen J. Sullivan     11,764,792       1,211,818       16,592,412  

 

 

Proposal 2: To approve the Interpace Diagnostics Group, Inc. 2019 Equity Incentive Plan.

 

For   Against   Abstain   Broker Non-Vote
  9,300,992       3,573,077       102,541       16,592,412  

 

 

Proposal 3: To approve the Interpace Diagnostics Group, Inc. Employee Stock Purchase Plan.

 

For   Against   Abstain   Broker Non-Vote
  10,208,651       2,719,748       48,211       16,592,412  

 

Proposal 4: To approve, under applicable Nasdaq Listing Rules, issuances of shares of the Company’s Common Stock upon conversion of the Company’s Preferred Stock in excess of 19.99% of the Company’s Common Stock outstanding prior to such issuances.

 

For   Against   Abstain   Broker Non-Vote
  12,187,415       706,869       82,326       16,592,412  

 

Proposal 5: To ratify the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.

 

For   Against   Abstain   Broker Non-Vote
  29,181,857       164,008       123,156       -  

 

Proposal 6: To adjourn the Annual Meeting.

 

For   Against   Abstain   Broker Non-Vote
  28,171,373       821,741       219,182       356,726  

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Interpace Diagnostics Group, Inc.
   
  /s/ Jack E. Stover
  Jack E. Stover
  President and Chief Executive Officer

 

Date: October 15, 2019

 

 
 

 

 

Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Interpace Biosciences Charts.

Interpace Biosciences (NASDAQ:IDXG)
Intraday Stock Chart

Today : Sunday 17 November 2019

Click Here for more Interpace Biosciences Charts.

Latest IDXG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.